EU validates Rigel marketing application for fostamatinib
European regulators have validated Rigel Pharmaceuticals’ application to market fostamatinib for adult chronic immune thrombocytopenia (ITP).
Read More
Tag: Repligen
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
